Compare · NVO vs SXTP
NVO vs SXTP
Side-by-side comparison of Novo Nordisk A/S (NVO) and 60 Degrees Pharmaceuticals Inc. (SXTP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SXTP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 54932.1x SXTP ($3.2M).
- NVO has been more active in the news (4 items in the past 4 weeks vs 3 for SXTP).
- NVO has more recent analyst coverage (25 ratings vs 0 for SXTP).
- Company
- Novo Nordisk A/S
- 60 Degrees Pharmaceuticals Inc.
- Price
- $38.82-1.05%
- $0.86-3.00%
- Market cap
- $173.66B
- $3.2M
- 1M return
- -
- -13.86%
- 1Y return
- -
- -85.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest SXTP
- 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
- SEC Form 8-K filed by 60 Degrees Pharmaceuticals Inc.
- 60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
- 60 Degrees Pharmaceuticals Inc. filed SEC Form 8-K: Other Events
- 60 Degrees Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- 60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
- SEC Form EFFECT filed by 60 Degrees Pharmaceuticals Inc.
- SEC Form DEL AM filed by 60 Degrees Pharmaceuticals Inc.
- SEC Form S-3 filed by 60 Degrees Pharmaceuticals Inc.
- 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results